VISCHER advised Kuros Biosciences

Kuros Biosciences completes a rights offering and share placement in which a total of 10,341,432 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 each were offered or placed, respectively, at an offer price of CHF 1.80 per share. Total gross proceeds raised from the capital increase amount to CHF 18.6m. Kuros intends to use the proceeds of the offering to accelerate and advance the commercial roll-out of its product MagnetOs and to advance the further clinical development of its product candidate Fibrin-PTH.

The team

VISCHER advised Kuros Biosciences with Matthias Staehelin (Partner, Corporate – pictured), Sebastian Flückiger (Associate, Corporate), Nadia Tarolli (Partner, Tax) and Adrian Briner (Senior Associate, Tax).

As previosuly reported by, Bär & Karrer acted as legal adviser to Octavian and Helvetische Bank in this transaction. The team included Thomas U. ReutterAlexander von Jeinsen and Carlo Hunter (all Capital Markets) as well as Christoph Suter and David Weimann (both Tax).